trending Market Intelligence /marketintelligence/en/news-insights/trending/M7vZLkkyb2AfO8plxZr_rA2 content esgSubNav
In This List

Fuji Pharma acquires 4.2% of biosimilar developer company Alvotech for $50M

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Fuji Pharma acquires 4.2% of biosimilar developer company Alvotech for $50M

Fuji Pharma Co. Ltd. acquired a 4.2% stake in Iceland-based biopharmaceutical company Alvotech for about $50 million.

Fuji Pharma and Alvotech entered into a partnership in November 2018 to develop and commercialize Alvotech's biosimilar portfolio in Japan. Under the partnership, Alvotech agreed to develop and supply multiple biosimilars, while Fuji will register and commercialize the assets in Japan.

According to Alvotech, the chairman of Tokyo-based Fuji Pharma will join the board of Alvotech following the investment.

Alvotech develops biosimilars to provide cost-competitive products to patients across the globe.